Qualigen therapeutics extends research agreement with university of louisville research foundation on ras program

Carlsbad, calif., march 15, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces the mutual extension of a research agreement with university of louisville research foundation (ulrf). the revised agreement expands the company's collaboration with the research institution to develop its ongoing ras-f platform currently in the discovery stage for solid tumors through q1 of 2023.
QLGN Ratings Summary
QLGN Quant Ranking